A Study of Compared Adjuvant Serplulimab and Trastuzuma and Chemotherapy vs Chemotherapy Only in Her-2 Positive Gastric Cancer With II-III Stage Following Curative Resection
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
• Lower age limit of research subjects 20 years old and upper age limit of 80 years old.
• Be proven to be primary adenocarcinoma of gastric cancer and staged II-III by pathological evidences
• R0 gastrectomy with D2 lymphadenectomy
• Her2+ diagnosed by Immunohistochemistry or FISH
• ECOG (ECOG score standard) performance status of 0 or 1 and expected to survive more than 6 months
• No contraindications, including normal peripheral blood routine, liver and kidney function and electrocardiogram （WBC≥3.5 x 109 /L, NEU≥1.2 x 109 /L,PLT≥90 x 109 /L and HGB≥80g/L).